ИНГИБИТОРЫ АПФ И НЕФРОПРОТЕКЦИЯ ПРИ ХРОНИЧЕСКИХ ЗАБОЛЕВАНИЯХ ПОЧЕК С ПРОТЕИНУРИЕЙ


Цитировать

Полный текст

Аннотация

Ингибиторы АПф тормозят необратимое ухудшение функции почек при хронических заболеваниях почек с протеинурией, что во многом объясняется их антипротеинурическим действием. Эталонными доказательствами нефропротективного действия ингибиторов АПф являются результаты исследований REIN и AASK, в которых применяли рамиприл

Об авторах

С В Моисеев

ГОУ ВПО ММА им. И.М. Сеченова Росздрава, Москва

ГОУ ВПО ММА им. И.М. Сеченова Росздрава, Москва

Г П Арутюнов

ГОУ ВПО РГМУ Росздрава, Москва

ГОУ ВПО РГМУ Росздрава, Москва

В В Фомин

ГОУ ВПО ММА им. И.М. Сеченова Росздрава, Москва

ГОУ ВПО ММА им. И.М. Сеченова Росздрава, Москва

S V Moiseev

G P Arutyunov

V V Fomin

Список литературы

  1. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 1998;339:1448-56.
  2. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol. Dial. Transplant. 1999;14(Suppl. 1):42-44.
  3. Dzau V.J., Berstein K., Celermajer K., et al. Pathophysiological and therapeutic importance of tissue ACE: a consensus report. Cardiovasc. Drugs Ther. 2002;16:149-60.
  4. Crowley S.D., Gurley S.B., Olivierio M.I., et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J. Clin. Invest. 2005;115:1092-99.
  5. Мухин Н.А., Козловская Л.В., Бобкова И.Н. Индуцируемые протеинурией механизмы ремоделирования тубуло-интерстиция и возможности нефропротекции при гломерулонефрите // Вестник РАМН. 2005. № 1. С. 3-8.
  6. Remuzzi G., Ruggenenti P., Perico N. Chronic renal disease: renoprotective benefits of renin-angiotensin system inhibition. Ann. Intern. Med. 2002;136:604-15.
  7. Тареева И.Е., Кутырина И.М., Николаев А.Ю. и др. Пути торможения развития хронической почечной недостаточности // Терапевтический архив. 2000. № 6. С. 9-14.
  8. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
  9. Chiurchiu C., Remuzzi G., Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in non-diabetic patients: the data of meta-analyses. J. Am. Soc. Nephrol. 2005;16:S58-S63.
  10. Zucchelli P., Zuccala A., Borghi A., et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452-58.
  11. van Essen G.G., Apperloo A.J., Rensam P.L., et al. Are angiotensin converting enzyme inhibitors superior to beta-blockers in retarding progressive renal function decline? Kidney Int. 1997;63(Suppl.):58-62.
  12. Кутырина И.М., Тареева И.Е., Герасименко О.И. и др. Использование ингибиторов ангиотензинпревращающего фермента при хронических диффузных заболеваниях почек // Терапевтический архив. 1995. № 5. С. 20-24.
  13. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996;334(15):939-45.
  14. Locatelli F., Carbarns I.R., Maschio G., et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int. 1997;63(Suppl.):S63-S66.
  15. Pisoni R., Faraone R., Ruggenenti P., et al. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. J. Nephrol. 2002;15(4):428-30.
  16. Götz R., Drechsler U., Heidbreder E., et al. Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome. Z. Kardiol. 1988;77(Suppl. 3):65-68.
  17. Marre M., Hallab M., Billiard A., et al. Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J. Cardiovasc. Pharmacol. 1991;18(Suppl. 2):S165-S168.
  18. O'Brien R.C., Cooper M.E., Allen T.J., et al. Ramipril reduces albuminuria in diabetic rats fed a high protein diet. Clin. Exp. Pharmacol. Physiol. 1989;16(8):675-80.
  19. Thaiss F., Haas C., Helmchen U., et al. Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology. Nephrol. Dial. Transplant. 1996;11(1):40-46.
  20. Trevisan R., Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am. J. Hypertens. 1995;8(9):876-83.
  21. Stenvinkel P., Bolinder J., Alvestrand A. Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy. Acta Diabetol. 1997;34(1):10-17.
  22. Fogari R., Zoppi A., Pasotti C., et al. Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function. J. Hum. Hypertens. 1995;9(2):131-35.
  23. Schnack C., Hoffmann W., Hopmeier P., et al. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia. 1996;39(12):1611-16.
  24. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857-63.
  25. Ruggenenti P., Perna A., Gherardi G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998;352(9136):1252-56.
  26. Ruggenenti P., Perna A., Mosconi L., et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int. 1998;53(5):1209-16.
  27. Ruggenenti P., Perna A., Benini R., et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J. Am. Soc. Nephrol. 1999;10(5):997-1006.
  28. Ruggenenti P., Perna A., Gherardi G., et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. 2000;35(6):1155-65.
  29. Ruggenenti P., Perna A., Remuzzi G. Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol. 2001;12(12):2832-37.
  30. Ruggenenti P., Pagano E., Tammuzzo L., et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int. 2001;59(1):286-94.
  31. Ruggenenti P., Perna A., Zoccali C., et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen) J. Am. Soc. Nephrol. 2000;11(1):88-96.
  32. Ruggenenti P., Perna A., Loriga G., et al.; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-46.
  33. Ruggenenti P., Perna A., Benini R., et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol. 1998;9(11):2096-101.
  34. Pedersen E.B., Bech J.N., Nielsen C.B., et al. A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two years. Scand. J. Clin. Lab. Invest. 1997;57(8):673-81.
  35. Fogari R., Zoppi A., Corradi L., et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J. Hum. Hypertens. 1999;13(1):47-53.
  36. Herlitz H., Harris K., Risler T., et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol. Dial. Transplant. 2001;16(11):2158-65.
  37. Pisoni R., Ruggenenti P., Sangalli F., et al. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int. 2002;62(3):1010-19.
  38. Russo L.M., Brammar G.C., Jerums G., et al. The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-beta expression. J. Hypertens. 2003;21(2):419-28.
  39. Grandaliano G., Ranieri E., Monno R., et al. Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression. Exp. Nephrol. 1999;7(3):229-35.
  40. Sebekova K., Gazdíkova K., Syrova D., et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J. Hum. Hypertens. 2003;17(4):265-70.
  41. Agodoa L.Y., Appel L., Bakris G.L., et al.; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J.A.M.A. 2001;285(21):2719-28.
  42. Contras G., Greene T., Agodoa L.Y., et al.; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Blood pressure control, drug therapy and kidney disease. Hypertension 2005;46:44-50.
  43. Wright J.T. Jr., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J.A.M.A. 2002;288(19):2421-31.
  44. Lea J., Greene T., Hebert L., et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch. Intern. Med. 2005;165(8):947-53.
  45. Norris K., Bourgoigne J., Gassman J., et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am. J. Kidney Dis. 2006;48(5):739-51.
  46. Soergel M., Verho M., Wuhl E., et al. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr. Nephrol. 2000;15(1-2):113-18.
  47. Wühl E., Mehls O., Schaefer F.; ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66(2):768-76.
  48. Seeman T., Dusek J., Vondrak K., et al. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. Am. J. Hypertens. 2004;17(5 Pt .1):415-20.
  49. Knoll G.A., Cantarovitch M., Cole E., et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation-study design. Nephrol. Dial. Transplant. 2008;23(1):354-58.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах